Exact Mass: 523.1743
Exact Mass Matches: 523.1743
Found 369 metabolites which its exact mass value is equals to given mass value 523.1743
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
deacetylisoipecoside
Isoipecoside in which the acetyl group attaced to the nitrogen is replaced by hydrogen.
Deacetylipecoside
An isoquinoline alkaloid consisting of beta-D-glucose having a (2S,3R,4S)-3-ethenyl-4-{[(1R)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolinium-1-yl]methyl}-5-(methoxycarbonyl)-3,4-dihydro-2H-pyran-2-yl group attached at the anomeric centre.
3-(N-Maleimidopropionyl)biocytin
Deoxyribonucleic acid
Hapten
Penfluridol
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AG - Diphenylbutylpiperidine derivatives D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Penfluridol (R-16341) is a potent, long-acting, first-generation, oral diphenylbutylpiperidine antipsychotic agent by targeting D2-like dopamine receptor. Penfluridol effectively inhibits TNFα-induced NF-κB activation and alleviates the severity of arthritis and colitis in vivo. Penfluridol is a Ca2+-calmodulin inhibitor. Penfluridol induces apoptosis and autophagy. Penfluridol is used for chronic schizophrenia, acute psychosis, Tourette syndrome and autoimmune diseases. Penfluridol inhibites the growth of E. faecalis planktonic cells with the MIC of 7.81 μg/ml[1][2][3][4].
Pralnacasan
PENFLURIDOL
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AG - Diphenylbutylpiperidine derivatives D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Penfluridol (R-16341) is a potent, long-acting, first-generation, oral diphenylbutylpiperidine antipsychotic agent by targeting D2-like dopamine receptor. Penfluridol effectively inhibits TNFα-induced NF-κB activation and alleviates the severity of arthritis and colitis in vivo. Penfluridol is a Ca2+-calmodulin inhibitor. Penfluridol induces apoptosis and autophagy. Penfluridol is used for chronic schizophrenia, acute psychosis, Tourette syndrome and autoimmune diseases. Penfluridol inhibites the growth of E. faecalis planktonic cells with the MIC of 7.81 μg/ml[1][2][3][4].
Anhydropseudophlegmacin-9,10-quinone-3-amino-8-O-methyl ether
4-(hydroxymethyl)phenyl 5-O-nicotinyl-beta-D-apiofuranosyl(1->2)-beta-D-glucopyranoside|cucurbitoside L
N-(3-Maleimidopropionyl)biocytin
Cys Cys Ile Trp
Cys Cys Leu Trp
Cys Cys Trp Ile
Cys Cys Trp Leu
Cys Asp Met Arg
Cys Asp Arg Met
Cys Asp Thr Trp
Cys Asp Trp Thr
Cys Glu Ser Trp
Cys Glu Trp Ser
Cys His His Gln
Cys His Gln His
Cys Ile Cys Trp
Cys Ile Trp Cys
Cys Leu Cys Trp
Cys Leu Trp Cys
Cys Met Asp Arg
Cys Met Arg Asp
Cys Gln His His
Cys Arg Asp Met
Cys Arg Met Asp
Cys Ser Glu Trp
Cys Ser Trp Glu
Cys Thr Asp Trp
Cys Thr Trp Asp
Cys Trp Cys Ile
Cys Trp Cys Leu
Cys Trp Asp Thr
Cys Trp Glu Ser
Cys Trp Ile Cys
Cys Trp Leu Cys
Cys Trp Ser Glu
Cys Trp Thr Asp
Asp Cys Met Arg
Asp Cys Arg Met
Asp Cys Thr Trp
Asp Cys Trp Thr
Asp Asp Phe Gln
Asp Asp Gln Phe
Asp Glu Phe Asn
Asp Glu Asn Phe
Asp Phe Asp Gln
Asp Phe Glu Asn
Asp Phe Gly Trp
Asp Phe Asn Glu
Asp Phe Gln Asp
Asp Phe Trp Gly
Asp Gly Phe Trp
Asp Gly Trp Phe
Asp Lys Met Met
Asp Met Cys Arg
Asp Met Lys Met
Asp Met Met Lys
Asp Met Met Gln
Asp Met Gln Met
Asp Met Arg Cys
Asp Asn Glu Phe
Asp Asn Phe Glu
Asp Gln Asp Phe
Asp Gln Phe Asp
Asp Gln Met Met
Asp Arg Cys Met
Asp Arg Met Cys
Asp Thr Cys Trp
Asp Thr Trp Cys
Asp Trp Cys Thr
Asp Trp Phe Gly
Asp Trp Gly Phe
Asp Trp Thr Cys
Glu Cys Ser Trp
Glu Cys Trp Ser
Glu Asp Phe Asn
Glu Asp Asn Phe
Glu Phe Asp Asn
Glu Phe Asn Asp
Glu Met Met Asn
Glu Met Asn Met
Glu Asn Asp Phe
Glu Asn Phe Asp
Glu Asn Met Met
Glu Ser Cys Trp
Glu Ser Trp Cys
Glu Trp Cys Ser
Glu Trp Ser Cys
Phe Asp Asp Gln
Phe Asp Glu Asn
Phe Asp Gly Trp
Phe Asp Asn Glu
Phe Asp Gln Asp
Phe Asp Trp Gly
Phe Glu Asp Asn
Phe Glu Asn Asp
Phe Gly Asp Trp
Phe Gly Trp Asp
Phe Asn Asp Glu
Phe Asn Glu Asp
Phe Gln Asp Asp
Phe Trp Asp Gly
Phe Trp Gly Asp
Gly Asp Phe Trp
Gly Asp Trp Phe
Gly Phe Asp Trp
Gly Phe Trp Asp
Gly Met Met Trp
Gly Met Trp Met
Gly Trp Asp Phe
Gly Trp Phe Asp
Gly Trp Met Met
His Cys His Gln
His Cys Gln His
His His Cys Gln
His His Gln Cys
His Gln Cys His
His Gln His Cys
Ile Cys Cys Trp
Ile Cys Trp Cys
Ile Trp Cys Cys
Lys Asp Met Met
Lys Met Asp Met
Lys Met Met Asp
Leu Cys Cys Trp
Leu Cys Trp Cys
Leu Trp Cys Cys
Met Cys Asp Arg
Met Cys Arg Asp
Met Asp Cys Arg
Met Asp Lys Met
Met Asp Met Lys
Met Asp Met Gln
Met Asp Gln Met
Met Asp Arg Cys
Met Glu Met Asn
Met Glu Asn Met
Met Gly Met Trp
Met Gly Trp Met
Met Lys Asp Met
Met Lys Met Asp
Met Met Asp Lys
Met Met Asp Gln
Met Met Glu Asn
Met Met Gly Trp
Met Met Lys Asp
Met Met Asn Glu
Met Met Gln Asp
Met Met Trp Gly
Met Asn Glu Met
Met Asn Met Glu
Met Asn Pro Tyr
Met Asn Tyr Pro
Met Pro Asn Tyr
Met Pro Tyr Asn
Met Gln Asp Met
Met Gln Met Asp
Met Arg Cys Asp
Met Arg Asp Cys
Met Ser Thr Trp
Met Ser Trp Thr
Met Thr Ser Trp
Met Thr Trp Ser
Met Trp Gly Met
Met Trp Met Gly
Met Trp Ser Thr
Met Trp Thr Ser
Met Tyr Asn Pro
Met Tyr Pro Asn
Asn Asp Glu Phe
Asn Asp Phe Glu
Asn Glu Asp Phe
Asn Glu Phe Asp
Asn Glu Met Met
Asn Phe Asp Glu
Asn Phe Glu Asp
Asn Met Glu Met
Asn Met Met Glu
Asn Met Pro Tyr
Asn Met Tyr Pro
Asn Asn Asn Tyr
Asn Asn Tyr Asn
Asn Pro Met Tyr
Asn Pro Tyr Met
Asn Tyr Met Pro
Asn Tyr Asn Asn
Asn Tyr Pro Met
Pro Met Asn Tyr
Pro Met Tyr Asn
Pro Asn Met Tyr
Pro Asn Tyr Met
Pro Tyr Met Asn
Pro Tyr Asn Met
Gln Cys His His
Gln Asp Asp Phe
Gln Asp Phe Asp
Gln Asp Met Met
Gln Phe Asp Asp
Gln His Cys His
Gln His His Cys
Gln Met Asp Met
Gln Met Met Asp
Arg Cys Asp Met
Arg Cys Met Asp
Arg Asp Cys Met
Arg Asp Met Cys
Arg Met Cys Asp
Arg Met Asp Cys
Ser Cys Glu Trp
Ser Cys Trp Glu
Ser Glu Cys Trp
Ser Glu Trp Cys
Ser Met Thr Trp
Ser Met Trp Thr
Ser Thr Met Trp
Ser Thr Trp Met
Ser Trp Cys Glu
Ser Trp Glu Cys
Ser Trp Met Thr
Ser Trp Thr Met
Thr Cys Asp Trp
Thr Cys Trp Asp
Thr Asp Cys Trp
Thr Asp Trp Cys
Thr Met Ser Trp
Thr Met Trp Ser
Thr Ser Met Trp
Thr Ser Trp Met
Thr Trp Cys Asp
Thr Trp Asp Cys
Thr Trp Met Ser
Thr Trp Ser Met
Trp Cys Cys Ile
Trp Cys Cys Leu
Trp Cys Asp Thr
Trp Cys Glu Ser
Trp Cys Ile Cys
Trp Cys Leu Cys
Trp Cys Ser Glu
Trp Cys Thr Asp
Trp Asp Cys Thr
Trp Asp Phe Gly
Trp Asp Gly Phe
Trp Asp Thr Cys
Trp Glu Cys Ser
Trp Glu Ser Cys
Trp Phe Asp Gly
Trp Phe Gly Asp
Trp Gly Asp Phe
Trp Gly Phe Asp
Trp Gly Met Met
Trp Ile Cys Cys
Trp Leu Cys Cys
Trp Met Gly Met
Trp Met Met Gly
Trp Met Ser Thr
Trp Met Thr Ser
Trp Ser Cys Glu
Trp Ser Glu Cys
Trp Ser Met Thr
Trp Ser Thr Met
Trp Thr Cys Asp
Trp Thr Asp Cys
Trp Thr Met Ser
Trp Thr Ser Met
Tyr Met Asn Pro
Tyr Met Pro Asn
Tyr Asn Met Pro
Tyr Asn Asn Asn
Tyr Asn Pro Met
Tyr Pro Met Asn
Tyr Pro Asn Met
MPB
Butyl 2-[[3-[[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)amino]carbonyl]-2-hydroxy-1-naphthyl]azo]benzoate
Sarecycline hydrochloride
C784 - Protein Synthesis Inhibitor > C1595 - Tetracycline Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic D003879 - Dermatologic Agents
Idoxifene
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent
Pralnacasan
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
Ibiglustat L-malate
C471 - Enzyme Inhibitor Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].
N-[4-[[5-[5-hydroxy-4-oxo-3-(phenylmethyl)-1,2-dihydroquinazolin-2-yl]-2-methoxyphenyl]methoxy]phenyl]acetamide
4-[(2S,3R,4S,5R,6S)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]-8-ethyl-1-hydroxy-10,12-dimethoxynaphtho[1,2-c]isochromen-6-one
N-[3-[3-(1-piperidinylsulfonyl)anilino]-2-quinoxalinyl]benzenesulfonamide
Asp-Phe-Asp-Gln
A tetrapeptide composed of L-aspartic acid, L-phenylalanine, L-aspartic acid and L-glutamine joined in sequence by peptide linkages.
[2-(4-Naphthalen-2-ylsulfonylpiperazin-1-yl)-2-oxoethyl] 2-[(3,5-dimethylbenzoyl)amino]acetate
N-[3-(1-azepanylsulfonyl)phenyl]-2-[4-(1H-indol-3-ylmethyl)-2,5-dioxo-1-imidazolidinyl]acetamide
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[4-(trifluoromethyl)phenyl]carbamoylamino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
4,4,4-trifluoro-N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]butanamide
4,4,4-trifluoro-N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]butanamide
4,4,4-trifluoro-N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]butanamide
N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide
N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide
N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide
N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide
N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide
N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide
N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide
2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(2-thiazolylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-phenoxyphenyl)methyl]acetamide
5-chloro-N-[(2R)-2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]-2-hydroxypropyl]-2-methoxybenzamide
(2E)-3-ethyl-2-[(2Z)-2-[[3-ethyl-6-[(E)-2-phenylethenyl]-1,3-benzothiazol-3-ium-2-yl]methylidene]butylidene]-5,6-dimethyl-1,3-benzothiazole
Ninerafaxstat (trihydrochloride)
Ninerafaxstat (IMB-1018972) trihydrochloride is a novel mitotropic agent. Ninerafaxstat trihydrochloride increases myocardial metabolic efficiency by shifting substrate utilization towards glucose through reducing fatty acid oxidation (inhibiting 3-ketoacyl CoA thiolase). Ninerafaxstat trihydrochloride can be used for the research of cardiovascular diseases[1].
(e,2z)-2-{[(2s)-2-amino-3-(3,4-dihydroxyphenyl)-1-hydroxypropylidene]amino}-n-[(1e)-2-(3,4-dihydroxyphenyl)ethenyl]-3-(3,4,5-trihydroxyphenyl)prop-2-enimidic acid
(1s,14s,15r)-14-hydroxy-15-{[(2r,3s,4s,5r,6r)-6-(hydroxymethyl)-3,4,5-trimethoxyoxan-2-yl]oxy}-5,7-dioxa-12-azatetracyclo[10.5.2.0²,¹⁰.0⁴,⁸]nonadeca-2,4(8),9-triene-13,17-dione
(4s,5r,6s)-5-ethenyl-4-{[(1s)-7-hydroxy-6-methoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylic acid
[9-(acetyloxy)-6-hydroxy-5a,8,11a-trimethyl-1-oxo-3-(pyridin-3-yl)-6,7,7a,9,10,11-hexahydro-2,5-dioxatetraphen-8-yl]methyl acetate
19-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-11-hydroxy-3-(hydroxymethyl)-9-methyl-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione
[(3s,4r,5s)-5-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[4-(hydroxymethyl)phenoxy]oxan-3-yl]oxy}-3,4-dihydroxyoxolan-3-yl]methyl pyridine-2-carboxylate
(13s)-8,9-dehydro-18,21-dihydroxy-10-epi-ryanodine
{"Ingredient_id": "HBIN001299","Ingredient_name": "(13s)-8,9-dehydro-18,21-dihydroxy-10-epi-ryanodine","Alias": "NA","Ingredient_formula": "C25H33NO11","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4906","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(13s)-8α,9α-epoxy-18-hydroxy-10-epi-ryanodine
{"Ingredient_id": "HBIN001301","Ingredient_name": "(13s)-8\u03b1,9\u03b1-epoxy-18-hydroxy-10-epi-ryanodine","Alias": "NA","Ingredient_formula": "C25H33NO11","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7110","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
8,9-dehydro-20,21-dihydroxy-10-epi-ryanodine
{"Ingredient_id": "HBIN013584","Ingredient_name": "8,9-dehydro-20,21-dihydroxy-10-epi-ryanodine","Alias": "NA","Ingredient_formula": "C25H33NO11","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4907","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
8α,9α-epoxy-20-hydroxy-10-epi-ryanodine
{"Ingredient_id": "HBIN013614","Ingredient_name": "8\u03b1,9\u03b1-epoxy-20-hydroxy-10-epi-ryanodine","Alias": "NA","Ingredient_formula": "C25H33NO11","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7111","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
8α,9α-epoxy-21-hydroxy-10-epi-ryanodine
{"Ingredient_id": "HBIN013615","Ingredient_name": "8\u03b1,9\u03b1-epoxy-21-hydroxy-10-epi-ryanodine","Alias": "NA","Ingredient_formula": "C25H33NO11","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7112","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}